A new systematic review and meta-analysis suggests that women with inflammatory bowel disease (IBD) may be at increased risk of adverse pregnancy outcomes such as gestational diabetes mellitus (GDM) and preterm premature rupture of membranes (PPROM).
A new systematic review and meta-analysis suggests that women with inflammatory bowel disease (IBD) may be at increased risk of adverse pregnancy outcomes such as gestational diabetes mellitus (GDM) and preterm premature rupture of membranes (PPROM). The authors caution, however, their results need to be confirmed in larger, prospective studies.
Published in Alimentary Pharmacology & Therapeutics, the findings are by Canadian researchers who searched Medline, Embase, and the Cochrane library through May 2019 for studies reporting adverse maternal, placental and obstetric outcomes in patients with IBD. Nearly 8000 pregnancies complicated by IBD and more than 3,200 control pregnancies were represented in the 53 studies selected for analysis.
The authors hypothesized that women who took medication for IBD during pregnancy might have an increased risk of adverse outcomes such as cesarean delivery, GDM, preeclampsia, chorioamnionitis, placental abruption, PPROM, early pregnancy loss, elective termination of pregnancy, termination of pregnancy, and ectopic pregnancy.
The medications considered were 5-aminosalicylates (5-ASA), corticosteroids, thiopurines, anti-tumor necrosis factor (TNF) therapy, vedolizumab, ustekinumab, and tofacitinib.
Analysis of the data from the studies showed that cesarean delivery was more common in patients with IBD compared to healthy controls (OR 1.79, 95% CI 1.16 to 2.77). This remained significant for ulcerative colitis but not Crohn’s disease (OR 1.48, 95% CI 0.94 to 2.34). GDM also was more common in women with IBD (OR 2.95, 95% CI 1.47 to 5.98).
Incidences of placental disease were 2.0% (95% CI 0.9% to 3.1%) for preeclampsia, 3.3% (95% CI 0% to 7.2%) for placental abruption, 0.5% (95% CI 0.2% to 0.9%) for placenta previa and 0.3% (95% CI 0% to 0.5%) for chorioamnionitis. Women with IBD were more likely to experience PPROM (OR 12.10, 95% CI 2.15 to 67.98) but not early pregnancy loss (OR 1.63, 95% CI 0.49 to 5.43).
Anti-TNF therapy was not associated with chorioamnionitis (OR 1.12, 95% CI 0.16 to 7.67), early pregnancy loss (OR 1.49, 95% CI 0.83 to 2.64) or placenta previa (OR 1.58, 95% CI 0.30 to 8.47).
The authors noted, however, that the study sample sizes were small and control group comparisons were lacking so definitive conclusions about the drugs cannot be made. They are, however, in line with recent guidelines from the American Gastroenterological Association to continue anti-TNF therapy in pregnant women to maintain IBD remission.
Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharm Ther. 2020;51(3):320-333. doi:10.1111/apt.15587.
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More